Achieve Life Sciences is projected to report a consensus EPS loss of $0.18 on zero revenue for Q2 2026, with the stock currently trading at $4.42 against an average analyst price target of $15.50. Investors are primarily focused on the definitive timeline for the New Drug Application (NDA) submission for cytisinicline, the company's lead smoking cessation candidate. Recent clinical progress and a strengthened balance sheet have reduced immediate financing risks, yet the path to FDA approval remains the central catalyst for valuation. Management's commentary regarding commercial readiness and potential strategic partnerships will be scrutinized to assess the long-term viability of the launch.